Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05874037 · ClinicalTrials.gov registry record · Phase 2
Fluvoxamine for Long COVID-19
A Phase 2 study of Long COVID, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 191
- Enrollment target
- 1
- Study location
NCT05874037: Completed Phase 2 study of Long COVID, sponsored by Washington University School of Medicine.
NCT05874037 is a Phase 2 study of Long COVID that has completed, run by Washington University School of Medicine. The registered enrollment target is 191 participants, below the 2,184-participant average among 50 other Long COVID trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05874037, a Phase 2 study of Long COVID, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 191 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial aims to test the effects of fluvoxamine as a treatment for Long COVID. Fluvoxamine is an FDA approved SSRI for Obsessive Compulsive Disorder (OCD), that has already had success in preventing hospitalization in patients with COVID-19 (STOP COVID and TOGETHER trials). This trial is testing whether fluoxamine helps to improve symptoms and the negative impacts of long COVID in residents of Missouri and Illinois.
Primary Outcome
Participants completed a self-report twice-daily questionnaire which asks about trouble concentrating, anxiety, depression and fatigue. Respondents rate how much of a problem the symptom is "right now" on a scale of 0 (no problem) to 100 (severe problem). Results compare the change in average total scores (of the four symptoms) from baseline and endpoint.
Conditions Studied
Interventions
- DRUG Fluvoxamine
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2023-05-15 |
| Est. Completion | 2025-03-15 |
| Phase | Phase 2 |
What the finished NCT05874037 record still lists
NCT05874037 is an interventional study that assigns participants to a tested intervention. The registered 191 participants enrollment target is mid-sized for trials with a published cap, below the 2,184-participant average among 50 other Long COVID trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Long COVID appearing as the primary indexed condition, and to 1 intervention - of which Fluvoxamine is the first listed.
NCT05874037 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT05874037 about?
NCT05874037 is a clinical study titled "Fluvoxamine for Long COVID-19". This clinical trial aims to test the effects of fluvoxamine as a treatment for Long COVID. Fluvoxamine is an FDA approved SSRI for Obsessive Compulsive Disorder (OCD), that has already had success in preventing hospitalization in patients with COVID-19 (STOP COVID and TOGETHER trials). This trial is...
What is the current status of trial NCT05874037?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 191 participants. The study started on 2023-05-15. Estimated completion is 2025-03-15.
What conditions does trial NCT05874037 study?
This clinical trial studies the following conditions: Long COVID.
What interventions are being tested in trial NCT05874037?
The interventions under investigation include: Fluvoxamine (DRUG).
Who is sponsoring clinical trial NCT05874037?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05874037 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Long COVID
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05874037's enrollment target sits among peer trials
191 18th of 50 higher than 33 of 50 other Long COVID trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Long COVID trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NE3107 in Adults With Neurological Symptoms of Long COVID
RECRUITING · Phase 2
-
Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)
RECRUITING · Phase 2
-
Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation
RECRUITING · Phase 2
-
AT1001 for the Treatment of Long COVID
RECRUITING · Phase 2
-
LIFT: Life Improvement Trial
RECRUITING · Phase 2
-
A Study to Examine Anktiva for the Treatment of COVID-19.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04621435 · 191 participants · Phase 1
Imaging of Solid Tumors Using FAP-2286
- NCT06810544 · 191 participants · Phase 1
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI